Esophageal Sphincter Augmentation: An Effective Option for Refractory Regurgitation in Patients with GERD

Magnetic sphincter augmentation, but not increasing PPI dose, improved regurgitation that was refractory to once-daily PPI.

Regurgitation is the most common refractory esophageal symptom in patients with well-established pathologic reflux. In a manufacturer-supported study, researchers assessed increased dosing of proton-pump inhibitor (PPI) therapy compared with magnetic sphincter augmentation (MSA) in 152 patients with gastroesophageal reflux disease (GERD) and refractory regurgitation despite once-daily PPI therapy. To assess resolution of regurgitation, participants completed quality-of-life surveys at baseline and 6 months; esophageal pH and daily number of reflux events were also measured.

Doubling the PPI dosing regimen to twice-daily 20-mg omeprazole produced resolution of regurgitation in 10% of the PPI group. By contrast, 89% of the MSA group achieved r…

Reviewing Author

Kenneth R. DeVault, MD

Disclosures

Consultant/Advisory BoardPhathom Pharmaceuticals

Grant/Research SupportIronwood Pharmaceuticals

Leadership Positions in Professional SocietiesAmerican College of Gastroenterology Education Universe (Co-Editor)

Kenneth R. DeVault, MD

Disclosures

Consultant/Advisory BoardPhathom Pharmaceuticals

Grant/Research SupportIronwood Pharmaceuticals

Leadership Positions in Professional SocietiesAmerican College of Gastroenterology Education Universe (Co-Editor)

Esophageal Sphincter Augmentation: An Effective Option for Refractory Regurgitation in Patients with GERD

Topics

Reviewing Author